Our work further suggest that in part by restoring DAB2IP expression to suppress cancer cell growth, proliferation and metastasis, Akt inhibitors or Fbw7/CKI inhibitors may be beneficial in treating various types of human cancers, particularly the metastatic cancers that are associated with poor survival rates. This evidence concerns the gene DAB2IP and metastatic malignant neoplasm.